Biocytogen and IDEAYA Biosciences push IDE034 into the clinic as dual-antigen ADC strategies mature
IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.
Pharma & Biotech
Pharma & Biotech
Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma
KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.
Pharma & Biotech
Why Merck and Eisai’s belzutifan–lenvatinib combo could reset treatment sequencing in advanced renal cell carcinoma
Belzutifan plus lenvatinib outperforms cabozantinib in Phase 3 renal cell carcinoma data. Find out what this changes for post-immunotherapy care.
Pharma & Biotech
Sciwind Biosciences and Pfizer China bet on ecnoglutide as China’s GLP-1 market enters its most competitive phase
Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.
Pharma & Biotech
Can STATHMIN-2 restoration succeed where ALS therapies have failed? QurAlis data examined
QurAlis ANQUR trial data puts STATHMIN-2 restoration on the ALS map. Find out what changes and what risks remain.
Pharma & Biotech
Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.
Pharma & Biotech
Why GSK’s expanded Bora Pharmaceuticals partnership reflects new CDMO selection logic
Explore what the Bora Pharmaceuticals and GSK manufacturing deal reveals about long-term supply strategy and CDMO market shifts. Read the full analysis.
Pharma & Biotech
TScan Therapeutics strengthens heme pipeline with dual IND clearances
TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.
Pharma & Biotech
Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors
Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.
Pharma & Biotech
Can X4 Pharmaceuticals and Norgine unlock EU access to the first targeted WHIM therapy?
EMA backs mavorixafor for WHIM syndrome. Explore what EU approval could mean for access, evidence standards, and rare immunology treatment.